About Zinc finger CCCH-type antiviral protein 1-like
Zinc finger CCCH-type antiviral protein 1-like (ZC3HAV1L) is a protein
from Homo sapiens identified by UniProt accession
Q96H79, 300 residues long.
MolForge cross-references it against 0 known binders and
27 disease associations.
Target properties
| Protein name | Zinc finger CCCH-type antiviral protein 1-like |
|---|
| UniProt accession | Q96H79 |
|---|
| Gene | ZC3HAV1L |
|---|
| Organism | Homo sapiens |
|---|
| Length | 300 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (27)
Diseases linked to this target (Open Targets).
- reticulocyte measurement · score 0.34
- Immature Reticulocyte Fraction Measurement · score 0.33
- monocyte count · score 0.33
- reticulocyte count · score 0.33
- IGF-1 measurement · score 0.23
- leukocyte count · score 0.22
- insulin like growth factor measurement · score 0.17
- platelet count · score 0.17
- multiple sclerosis · score 0.17
- myeloid white cell count · score 0.16
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96H79-F1 | alphafold | PREDICTED | 82.46 | — |
Amino-acid sequence (300 residues)
MAEPTVCSFL TKVLCAHGGR MFLKDLRGHV ELSEARLRDV LQRAGPERFL LQEVETQEGL GDAEAEAAAG AVGGGGTSAW RVVAVSSVRL CARYQRGECQ ACDQLHFCRR HMLGKCPNRD CWSTCTLSHD IHTPVNMQVL KSHGLFGLNE NQLRILLLQN DPCLLPEVCL LYNKGEALYG YCNLKDKCNK FHVCKSFVKG ECKLQTCKRS HQLIHAASLK LLQDQGLNIP SVVNFQIIST YKHMKLHKML ENTDNSSPST EHSQGLEKQG VHAAGAAEAG PLASVPAQSA KKPCPVSCEK
Explore Zinc finger CCCH-type antiviral protein 1-like with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets